Artificial Blood Vessels Market – Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Application (Aortic Disease, Peripheral Artery Disease, Haemodialysis), By Polymer (Polydioxanone, Elastomer, Polyethylene Terephthalate, Others), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 339.41 Million
CAGR (2026-2031)	6.03%
Fastest Growing Segment	Aortic Disease
Largest Market	Middle East & Africa
Market Size (2031)	USD 482.28 Million

Market Overview

The Global Artificial Blood Vessels Market is projected to grow from USD 339.41 Million in 2025 to USD 482.28 Million by 2031 at a 6.03% CAGR. Artificial blood vessels are synthetic conduits designed to replace or bypass damaged arteries and veins in patients suffering from vascular compromise. The expansion of this market is fundamentally driven by the rising incidence of cardiovascular conditions and an aging global population that increasingly requires surgical vascular reconstruction. According to the American Heart Association, in 2024, cardiovascular disease constituted the leading cause of global mortality and accounted for approximately one third of all deaths worldwide. This critical health burden sustains a high demand for effective vascular graft solutions to restore proper blood flow.

Despite this demand, the industry encounters a significant challenge related to the long term biocompatibility of synthetic materials. Small diameter grafts frequently fail due to surface thrombosis or infection which leads to vessel occlusion and necessitates reoperation. These persistent failure rates impede broader market adoption and drive the continual need for superior materials that better mimic natural vascular performance.

Key Market Drivers

The surging incidence of diabetes and lifestyle-related vascular complications stands as a primary catalyst propelling the Global Artificial Blood Vessels Market. Sustained hyperglycemia in diabetic patients significantly accelerates atherosclerosis and endothelial damage, frequently culminating in peripheral artery disease (PAD) that necessitates surgical bypass using synthetic conduits. This systemic vascular deterioration creates a critical need for durable grafts, particularly when autologous veins are unsuitable or unavailable due to patient comorbidities. According to the International Diabetes Federation, 2025, in the 'IDF Diabetes Atlas 11th Edition', an estimated 589 million adults were living with diabetes in 2024, representing a massive patient population increasingly susceptible to complex vascular pathologies requiring intervention. The resulting operational burden is evident in regional surgical data; according to the Australian and New Zealand Society for Vascular Surgery, March 2025, in the 'Australasian Vascular Audit Public Report 2024', surgeons recorded 52,217 vascular operations in the registry for the year, highlighting the substantial volume of procedures driven by vascular compromise.

Simultaneously, the rising demand for vascular access grafts in hemodialysis treatment significantly bolsters market growth. As the prevalence of end-stage renal disease (ESRD) climbs, a growing number of patients require reliable vascular access points, such as arteriovenous grafts, to facilitate life-sustaining blood filtration therapies when natural fistulas fail or cannot be established. These synthetic grafts are essential consumables in the management of chronic kidney failure. According to Fresenius Medical Care, March 2025, in the 'Annual Report 2024', approximately 4.2 million patients worldwide regularly undergo dialysis treatment, ensuring a continuous and expanding necessity for effective vascular access solutions to support this critical care infrastructure.

Download Free Sample Report

Key Market Challenges

The inherent lack of long-term biocompatibility in synthetic materials stands as the primary challenge impeding the growth of the Global Artificial Blood Vessels Market. In small-diameter applications, synthetic grafts frequently trigger adverse biological responses, such as surface thrombosis and intimal hyperplasia, shortly after implantation. These complications often result in vessel occlusion, rendering the graft ineffective and necessitating risky reoperation. This reliability gap forces vascular surgeons to prioritize autologous vein harvesting over off-the-shelf synthetic options, thereby severely restricting the commercial volume and adoption rate of artificial conduits in standard practice.

The economic and clinical burden of these failure rates further suppresses market expansion. Healthcare providers face increased costs associated with monitoring and correcting failing grafts, creating a cautious procurement environment for synthetic technologies. According to the Society for Vascular Surgery, in 2025, synthetic infrainguinal bypass grafts exhibited a primary patency failure rate of nearly 30% within the first year of implantation. Such statistics highlight a critical performance deficit compared to natural vessels. Consequently, until synthetic materials can demonstrate superior durability, the market will remain constrained by a lack of trust and high post-procedural maintenance requirements.

Key Market Trends

The Advancement in Biodegradable and Bioresorbable Polymer Scaffolds represents a critical technological evolution in the market, moving beyond permanent synthetic implants that often restrict natural vessel physiology. This trend focuses on developing temporary scaffolds that provide mechanical support during the healing phase and then gradually dissolve, thereby allowing the blood vessel to resume natural vasomotion and reducing the risk of long-term inflammation or thrombosis. This shift addresses the limitations of permanent metallic stents, particularly in peripheral artery disease applications where vessel flexibility is paramount. The clinical viability of this technology is increasingly validated by strong performance data. According to Cardiovascular Business, August 2025, in the 'Abbott's dissolving stent picks up a key approval' article, two-year results for the Esprit BTK System demonstrated that 90.3% of patients treated with the bioresorbable scaffold did not require reintervention, highlighting its potential to set a new standard of care for below-the-knee interventions.

Simultaneously, the Shift Toward Acellular and Decellularized Tissue-Engineered Grafts is redefining the availability and efficacy of vascular replacements. Unlike traditional synthetic grafts made from PTFE or Dacron, these bioengineered vessels are designed to be available off-the-shelf while retaining the biological properties necessary to resist infection and promote host cell integration. This trend is rapidly transitioning from clinical research to commercial reality, offering a scalable solution that mimics native tissue without the wait time associated with autologous harvesting. The immediate market traction of such innovations is evident in their early adoption rates following regulatory milestones. According to Humacyte, Inc., March 2025, in the 'Fourth Quarter and Year End 2024 Financial Results', 34 hospitals had already initiated the Value Analysis Committee (VAC) approval process for the company's newly approved acellular tissue-engineered vessel within just 16 days of its commercial inventory availability, signaling strong demand for biologic alternatives in trauma and vascular reconstruction.

Segmental Insights

The Aortic Disease segment is emerging as the fastest-growing category within the global artificial blood vessels market. This surge is primarily attributed to the increasing prevalence of aortic aneurysms and dissections in the aging global population. The market is further propelled by a widespread clinical transition from open surgery to minimally invasive endovascular procedures, which rely heavily on specialized synthetic grafts. Moreover, continuous device clearances by the U.S. Food and Drug Administration have broadened treatment accessibility. These factors collectively drive the robust demand for aortic interventions in healthcare facilities worldwide.

Regional Insights

The Middle East & Africa commands a leading position in the Global Artificial Blood Vessels Market, driven by an escalating prevalence of cardiovascular diseases and lifestyle-related conditions such as diabetes. This distinct surge in clinical demand is met with aggressive healthcare modernization efforts, exemplified by initiatives like Saudi Vision 2030, which prioritize advanced surgical infrastructure. Furthermore, regulatory bodies such as the Saudi Food and Drug Authority are streamlining the approval processes for synthetic grafts, facilitating rapid market access. This convergence of urgent patient needs and substantial government investment establishes the region as a dominant force in the global sector.

Recent Developments

• In April 2025, W. L. Gore & Associates announced the U.S. Food and Drug Administration (FDA) approval and subsequent commercial launch of new large-diameter tapered configurations for the GORE TAG Conformable Thoracic Stent Graft with ACTIVE CONTROL System. These new device options were engineered to provide vascular surgeons with greater flexibility in treating patients with thoracic aortic disease, particularly those presenting with complex anatomical disparities between proximal and distal landing zones. The introduction of these tapered stent grafts was intended to optimize the seal and fixation within the aorta, thereby potentially improving long-term patient outcomes and expanding the applicability of endovascular repair therapies.
• In December 2024, Humacyte, Inc. received full approval from the U.S. Food and Drug Administration (FDA) for its acellular tissue engineered vessel (ATEV), marketed under the brand name SYMVESS. The regulatory approval authorized the use of this bioengineered human tissue product for the treatment of extremity vascular trauma in adults when standard autologous vein grafts are not feasible. This event marked a major breakthrough in the artificial blood vessels sector, establishing a new category of "off-the-shelf" bio-integrative tissues available for urgent surgical use. The company emphasized that the vessel is designed to be universally implantable and to remodel into the patient's own living tissue over time.
• In November 2024, Xeltis announced that it had received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its aXess vascular access conduit. Coinciding with this regulatory milestone, the company confirmed the successful treatment of the first patient in its pivotal clinical trial in the United States. The aXess device represents a significant innovation in the market, designed as a restorative implant that enables the body to create a new, permanent, living vessel for hemodialysis access. This development highlights the industry's shift towards endogenous tissue restoration, aiming to overcome the durability and infection limitations often associated with traditional synthetic vascular grafts.
• In August 2024, Terumo India, a subsidiary of Terumo Corporation, announced the launch of the TREO Stent-Graft System to address the treatment needs of patients with infrarenal abdominal aortic aneurysms. This new product introduction brought to the market a unique endovascular aneurysm repair (EVAR) solution featuring both suprarenal and infrarenal active fixation for enhanced graft stability. The system was designed to accommodate a wide range of aortic anatomies, offering features such as in-situ limb adjustability and a detachable sheath for precise deployment. This strategic launch aimed to expand the company’s portfolio of advanced aortic care solutions in the region, providing clinicians with a versatile option for managing complex vascular repairs.

Key Market Players

• B. Braun Melsungen
• Becton, Dickinson and Company
• Cook Medical Incorporated
• Humacyte Inc.
• Jotec GmbH
• LeMaitre Vascular Inc
• Medtronic Inc
• Techshot Inc
• Terumo Medical Corporation
• W. L. Gore & Associates, Inc.

By Application	By Polymer	By Region
Aortic Disease Peripheral Artery Disease Haemodialysis	Polydioxanone Elastomer Polyethylene Terephthalate Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Artificial Blood Vessels Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Artificial Blood Vessels Market, By Application:

• Aortic Disease
• Peripheral Artery Disease
• Haemodialysis

• Artificial Blood Vessels Market, By Polymer:

• Polydioxanone
• Elastomer
• Polyethylene Terephthalate
• Others

• Artificial Blood Vessels Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE